Minireview: Live and Let Die: Molecular Effects of Glucocorticoids on Bone Cells
Open accessThe DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.
Abstract
Glucocorticoids (GCs) are efficient drugs that are used to treat various immune-mediated diseases, but their long-term administration is associated with multiple metabolic side effects, including osteoporosis. Molecular analyses of the mechanisms exerted by the GC receptor have resulted in the development of GC receptor agonists that selectively repress or activate GC target genes. This review summarizes the cellular and molecular effects of GCs on bone cells and highlights the critical signaling pathways that may evolve into future therapeutic strategies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Mechanisms involved in the side effects of glucocorticoids
SCHACKE, H. (2002) · Pharmacology & Therapeutics · doi:10.1016/s0163-7258(02)00297-8 · Cited by 1,847
Weinstein, R. S., Jilka, R. L., Parfitt, A. M., & Manolagas, S. C. (1998) · Journal of Clinical Investigation · doi:10.1172/jci2799 · Cited by 1,753 · cited 1×
“Histomorphometric studies of patients and experimental animal models revealed a reduced bone formation rate and trabecular wall thickness due to reduced numbers of osteoblasts as well as enhanced apoptosis of mature osteoblasts and osteocytes (16, 17).”
Background11β-Hydroxysteroid dehydrogenase type 1: a tissue specific regulator of glucocorticoid response
Tomlinson, J. W., Walker, E. A., Bujalska, I. J., Draper, N., Lavery, G. G., Cooper, M. S., Hewison, M., & Stewart, P. M. (2004) · Endocrine Reviews · doi:10.1210/er.2003-0031 · Cited by 969
Hofbauer, L. C., Gori, F., Riggs, B. L., Lacey, D. L., Dunstan, C. R., Spelsberg, T. C., & Khosla, S. (1999) · Endocrinology · doi:10.1210/endo.140.10.7034 · Cited by 794
Self-citationVan Staa, T. P., Laan, R. F., Barton, I. P., Cohen, S., Reid, D. M., & Cooper, C. (2003) · Arthritis & Rheumatism · doi:10.1002/art.11283 · Cited by 559
Schäcke, H., Schottelius, A., Döcke, W.-D., Strehlke, P., Jaroch, S., Schmees, N., Rehwinkel, H., Hennekes, H., & Asadullah, K. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0300372101 · Cited by 466
Glucocorticoids Act Directly on Osteoclasts to Increase Their Life Span and Reduce Bone Density
Jia, D., O’Brien, C. A., Stewart, S. A., Manolagas, S. C., & Weinstein, R. S. (2006) · Endocrinology · doi:10.1210/en.2006-0459 · Cited by 394
Glucocorticoids suppress bone formation via the osteoclast.
Kim, H.-J. (2006) · Journal of Clinical Investigation · doi:10.1172/jci28084 · Cited by 384 · cited 1×
“Disruption of the osteoclastic cytoskeleton due to decreased activation of rhoA, rac, and vav3 through macrophage colony-stimulating factor was identified as the underlying mechanism (36).”
BackgroundHuman Glucocorticoid Receptor β Binds RU-486 and Is TranscriptionallyActive
Lewis-Tuffin, L. J., Jewell, C. M., Bienstock, R. J., Collins, J. B., & Cidlowski, J. A. (2007) · Molecular and Cellular Biology · doi:10.1128/mcb.01439-06 · Cited by 175 · cited 1×
“However, this concept has been challenged by a recent study showing that, after binding of certain ligands such as the GR antagonist RU-486, GR is able to translocate into the nucleus independently of GR and modify the gene expression pattern of target cells (12).”
BackgroundDiederich, S., Eigendorff, E., Burkhardt, P., Quinkler, M., Bumke-Vogt, C., Rochel, M., Seidelmann, D., Esperling, P., Oelkers, W., & Bähr, V. (2002) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2002-020970 · Cited by 154
Effects of dissociated glucocorticoids on OPG and RANKL in osteoblastic cells.
Humphrey, E. L., Williams, J. H. H., Davie, M. W. J., & Marshall, M. J. (2006) · Bone · doi:10.1016/j.bone.2005.10.004 · Cited by 139
Yao, W., Cheng, Z., Pham, A., Busse, C., Zimmermann, E. A., Ritchie, R. O., & Lane, N. E. (2008) · Arthritis & Rheumatism · doi:10.1002/art.23954 · Cited by 128
Cited by
Pathogenesis of glucocorticoid-induced osteoporosis and options for treatment
Chotiyarnwong, P., & McCloskey, E. V. (2020) · Nature Reviews Endocrinology · doi:10.1038/s41574-020-0341-0 · Cited by 489
Joint IOF-ECTS GIO Guidelines Working Group, Lekamwasam, S., Adachi, J. D., Agnusdei, D., Bilezikian, J., Boonen, S., Borgström, F., Cooper, C., Diez Perez, A., Eastell, R., et al. (2012) · Osteoporosis International · doi:10.1007/s00198-012-1958-1 · Cited by 335
Self-citationMaps and legends: the quest for dissociated ligands of the glucocorticoid receptor
Clark, A. R., & Belvisi, M. G. (2012) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2011.12.004 · Cited by 209
“Perhaps the most troublesome side effect is osteoporosis, which particularly weakens trabecular bone and significantly increases the risk of fractures of spine, hips and ribs (Kanis et al., 2007; Hofbauer & Rauner, 2009; Weinstein, 2011).”
Involvement of the gut microbiota and barrier function in glucocorticoid-induced osteoporosis
Schepper, J. D., Collins, F., Rios-Arce, N. D., Kang, H. J., Schaefer, L., Gardinier, J. D., Raghuvanshi, R., Quinn, R. A., Britton, R., Parameswaran, N., et al. (2020) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.3947 · Cited by 199
Lan, G.-B., Xie, X.-B., Peng, L.-K., Liu, L., Song, L., & Dai, H.-L. (2015) · BioMed Research International · doi:10.1155/2015/413169 · Cited by 46
Metadata
- Authors
- Hofbauer, L. C., & Rauner, M.
- Venue
- Molecular Endocrinology
- Publisher
- The Endocrine Society
- Published
- 2009-10-01
- Volume
- 23
- Issue
- 10
- Pages
- 1525-1531
- ISSN
- 0888-8809 (ISSN-L)
- 1944-9917
- OpenAlex
- W1964436256
- Cited by
- 91
- References
- 12
- FWCI
- 3.39
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.